J1335
J1335 – Injection, ertapenem sodium, 500 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 19 NDCs crosswalked per 500 MG $6.750/unit ASP+6%
📋 J1335 summary
J1335 is a HCPCS Level II J-code used to bill ertapenem sodium, 500 mg, billed per 500 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J1335: Ertapenem, Invanz
Code J1335
Billing unit 500 MG Payment limit $6.750/unit NDC-Crosswalk 19
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ1335
DescriptorInjection, ertapenem sodium, 500 mg
Billing unit500 MG
Payment limit / unit$6.750
Est. ASP / unit$6.368 est.
Mapped NDCs19
Data periodQ3 2026
Last updated2026-08-20
💊 About Ertapenem Injection DRUG GUIDE
Ertapenem injection (brand name Invanz) is used to treat moderate to severe infections in adults and children 3 months and older, including complicated abdominal infections, complicated skin and skin structure infections (including diabetic foot infections without bone infection), community-acquired pneumonia, complicated urinary tract infections including pyelonephritis (kidney infection), and acute pelvic infections such as postpartum uterine infection, septic abortion, and post-surgical gynecologic infections.In adults only, Invanz is also used to prevent surgical site infection following elective colorectal surgery.
It works only against infections caused by bacteria that are susceptible to it — it will not treat viral infections.
Clinical overview from our editorial drug guide for Ertapenem Injection. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$6.750
Est. ASP / unit
$6.368 est.
Est. after 2% sequester
$6.615
HCPCS dosage
500 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, ertapenem sodium, 500 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment group—
Action codeN — No maintenance this year
Effective date2004-01-01
Date added2004-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J1335 = 500 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J1335 LEAST EXPENSIVE FIRST
19 NDCs map to J1335. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($6.750/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 00143-9398-10 | ertapenem sodium 1 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Hikma | 10 VIAL, SINGLE-DOSE in 1 CARTON (0143-939... | 1 g/1 | 20 | $135.00 | $27.755 | ● Active | CMS + PDAC |
| 00409-3510-22 | Ertapenem 1 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Hospira, | 10 VIAL, SINGLE-DOSE in 1 CARTON (0409-351... | 1 g/1 | 20 | $135.00 | $27.755 | ● Active | CMS + PDAC |
| 16714-0889-10 | ERTAPENEM SODIUM 1 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | NorthStar | 10 VIAL, SINGLE-DOSE in 1 CARTON (16714-88... | 1 g/1 | 20 | $135.00 | $27.755 | ● Active | CMS + PDAC |
| 42023-0221-10 | ERTAPENEM 1 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | ENDO | 10 VIAL, SINGLE-DOSE in 1 PACKAGE (42023-2... | 1 g/1 | 20 | $135.00 | $27.755 | ● Active | CMS + PDAC |
| 42023-0221-85 | ERTAPENEM 1 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | ENDO | 10 VIAL, SINGLE-DOSE in 1 PACKAGE (42023-2... | 1 g/1 | 20 | $135.00 | $27.755 | ● Active | CMS + PDAC |
| 43598-0901-58 | ERTAPENEM SODIUM 1 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Dr.Reddys | 10 VIAL, SINGLE-DOSE in 1 CARTON (43598-90... | 1 g/1 | 20 | $135.00 | $27.755 | ● Active | CMS + PDAC |
| 44567-0820-10 | ertapenem 1 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | WG | 10 VIAL, SINGLE-DOSE in 1 CARTON (44567-82... | 1 g/1 | 20 | $135.00 | $27.755 | ● Active | CMS + PDAC |
| 55150-0282-09 | Ertapenem 1 g/1 INJECTION | Eugia | 10 VIAL, SINGLE-DOSE in 1 CARTON (55150-28... | 1 g/1 | 20 | $135.00 | $27.755 | ● Active | CMS + PDAC |
| 55150-0282-20 | Ertapenem 1 g/1 INJECTION | Eugia | 10 VIAL, SINGLE-DOSE in 1 CARTON (55150-28... | 1 g/1 | 20 | $135.00 | $27.755 | ● Active | CMS + PDAC |
| 60505-6196-04 | Ertapenem 1 g/20mL INJECTION | Apotex | 10 VIAL in 1 CARTON (60505-6196-4) / 20 m... | 1 g/20mL | 20 | $135.00 | $27.755 | ● Active | CMS + PDAC |
| 63323-0823-20 | Ertapenem 1 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Fresenius | 10 VIAL, SINGLE-DOSE in 1 CARTON (63323-82... | 1 g/1 | 20 | $135.00 | $27.755 | ● Active | CMS + PDAC |
| 68001-0408-31 | Ertapenem 1 g/20mL INJECTION | BluePoint | 10 VIAL in 1 CARTON (68001-408-31) / 20 m... | 1 g/20mL | 20 | $135.00 | $27.755 | ● Active | CMS + PDAC |
| 72266-0159-10 | Ertapenem 1 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Fosun | 10 VIAL, SINGLE-DOSE in 1 CARTON (72266-15... | 1 g/1 | 20 | $135.00 | $27.755 | ● Active | CMS + PDAC |
| 72266-0159-05 | Ertapenem 1 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Fosun | 5 VIAL, SINGLE-DOSE in 1 CARTON (72266-159... | 1 g/1 | 10 | $67.50 | $51.201 | ● Active | CMS + PDAC |
| 00143-9429-10 | Ertapenem 1 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Hikma | 10 VIAL, SINGLE-DOSE in 1 CARTON (0143-942... | 1 g/1 | 20 | $135.00 | — | ● Active | CMS + PDAC |
| 25021-0199-20 | Ertapenem 1 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Sagent | 10 VIAL in 1 CARTON (25021-199-20) / 1 IN... | 1 g/1 | 20 | $135.00 | — | ● Active | CMS + PDAC |
| 25021-0199-66 | Ertapenem 1 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Sagent | 10 VIAL in 1 CARTON (25021-199-66) / 1 IN... | 1 g/1 | 2 | $13.50 | — | ● Active | PDAC |
| 43598-0901-11 | ERTAPENEM (SDV,LYOPHILIZED) 1 GM | Unknown | — | — | 2 | $13.50 | — | — | PDAC |
| 00006-3843-71 | INVANZ ertapenem sodium 1 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Merck | 10 VIAL, SINGLE-DOSE in 1 PACKAGE (0006-38... | 1 g/1 | 2 | $13.50 | — | ● Active | PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$254.7K
Claims
12,875
Beneficiaries
1,873
Spend / beneficiary
$135.97
Spend / claim
$19.78
Trend by period
Where J1335 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #507 of 824
#502
YUTIQ J7314
$263.2K
#503
MITOMYCIN J9280
$262.7K
#504
GADOTERIDOL* A9579
$262K
#505
BEIZRAY-ALBUMIN* J9174
$258.2K
#506
CYCLOPHOSPHAMIDE(J90... J9071
$255.9K
#507
ERTAPENEM J1335
$254.7K
#508
SURGRAFT TL, PER SQ... Q4263
$246.1K
#509
CAMPTOSAR* J9206
$245.5K
#510
EPIEFFECT, PER SQ CM... Q4278
$240.8K
#511
CEFTRIAXONE J0696
$239.8K
#512
KHAPZORY J0642
$235.8K
Total claims — #147 of 824
#142
GENTAMICIN SULFATE I... J1580
13,327
#143
ALIMTA* J9305
13,253
#144
TECENTRIQ J9022
13,217
#145
HIZENTRA J1559
13,119
#146
IPRATROPIUM BROMIDE J7644
12,953
#147
ERTAPENEM J1335
12,875
#148
ENGERIX-B ADULT(9074... 90746
12,582
#149
PYRIDOXINE HCL J3415
12,475
#150
FULPHILA Q5108
12,305
#151
FASENRA PEN* J0517
12,132
#152
FASLODEX* J9395
12,034
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $254.7K | 1,873 | 12,875 | $135.97 | $19.78 |
| 2025 (Q1-Q4) | $1.32M | 6,970 | 63,490 | $189.11 | $20.76 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$1.31M
Medicare paid
$1.02M
Submitted services
259,778
Denial rate
48.2%
Allowed / service
$9.70
Submitted charges
$26.32M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J1335 is utilized CMS · BY PROVIDER · 2024
Medicare Part B services for this code by the rendering provider's state — 92,228 services across 30 states & territories in 2024 (CMS reports include DC and U.S. territories). Switch to per 100k to compare states fairly regardless of population. Hover or tap a state for its top ZIP codes.
Hover or tap a state to see its numbers + top ZIP codes.
Per-capita = services ÷ 2023 state population × 100,000 (so high-population states aren't automatically "hotter"). Counts reflect the provider's location, not the patient's. Providers with fewer than 11 patients are hidden by CMS for privacy, so totals run low and per-100k can be noisy in small states — read this as relative geography, not exact counts. Source: CMS Medicare Physician & Other Practitioners — by Provider and Service, 2024.
📊 What bills under J1335
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
19 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J1335 billing FAQ
What is HCPCS code J1335?
J1335 is a HCPCS Level II J-code used to bill Injection, ertapenem sodium, 500 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J1335?
One unit of J1335 represents 500 MG. Report the number of units equal to the dose administered divided by 500 MG.
How many units of J1335 should I bill?
Divide the dose administered by the code's unit size (500 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J1335?
The Medicare Part B payment limit is $6.750 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $6.615 per unit. Payment limits are revised quarterly.
Which NDCs bill under J1335?
19 NDCs currently map to J1335 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J1335 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.